2021-13252. Bulk Manufacturer of Controlled Substances Application: Cambrex Charles City  

  • Start Preamble

    AGENCY:

    Drug Enforcement Administration, Justice.

    Start Printed Page 33359

    ACTION:

    Notice of application.

    SUMMARY:

    Cambrex Charles City has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

    DATES:

    Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 23, 2021. Such persons may also file a written request for a hearing on the application on or before August 23, 2021.

    ADDRESSES:

    Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In accordance with 21 CFR 1301.33(a), this is notice that on May 6, 2021, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 50616-3466, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

    Controlled substanceDrug codeSchedule
    Gamma Hydroxybutyric Acid2010I
    Tetrahydrocannabinols7370I
    Amphetamine1100II
    Lisdexamfetamine1205II
    Methylphenidate1724II
    ANPP (4-Anilino-N-phenethyl-4-piperidine)8333II
    Phenylacetone8501II
    Codeine9050II
    Oxycodone9143II
    Hydromorphone9150II
    Hydrocodone9193II
    Methadone9250II
    Morphine9300II
    Oripavine9330II
    Thebaine9333II
    Opium extracts9610II
    Opium fluid extract9620II
    Opium tincture9630II
    Opium, powdered9639II
    Oxymorphone9652II
    Noroxymorphone9668II
    Fentanyl9801II

    The company plans to manufacture the above-listed controlled substances in bulk for conversion to other controlled substances and sales to its customers for dosage form development, clinical trials and use in stability qualification studies. In reference to drug code 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture this drug as synthetic. No other activities for these drug codes are authorized for this registration.

    Start Signature

    William T. McDermott,

    Assistant Administrator.

    End Signature End Supplemental Information

    [FR Doc. 2021-13252 Filed 6-23-21; 8:45 am]

    BILLING CODE P

Document Information

Published:
06/24/2021
Department:
Drug Enforcement Administration
Entry Type:
Notice
Action:
Notice of application.
Document Number:
2021-13252
Dates:
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 23, 2021. Such persons may also file a written request for a hearing on the application on or before August 23, 2021.
Pages:
33358-33359 (2 pages)
Docket Numbers:
Docket No. DEA-857
PDF File:
2021-13252.pdf